PortalPublikationenInventory of economic evaluation of head and neck oncology f...

Inventory of economic evaluation of head and neck oncology from the German perspective

Standard

Inventory of economic evaluation of head and neck oncology from the German perspective. / Kurzweg, Thiemo; Knecht, R.

in: EUR ARCH OTO-RHINO-L, Jahrgang 271, Nr. 10, 09.01.2014, S. 2611-2616.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kurzweg, T & Knecht, R 2014, 'Inventory of economic evaluation of head and neck oncology from the German perspective', EUR ARCH OTO-RHINO-L, Jg. 271, Nr. 10, S. 2611-2616. https://doi.org/10.1007/s00405-013-2878-1

APA

Kurzweg, T., & Knecht, R. (2014). Inventory of economic evaluation of head and neck oncology from the German perspective. EUR ARCH OTO-RHINO-L, 271(10), 2611-2616. https://doi.org/10.1007/s00405-013-2878-1

Vancouver

Kurzweg T, Knecht R. Inventory of economic evaluation of head and neck oncology from the German perspective. EUR ARCH OTO-RHINO-L. 2014 Jan 9;271(10):2611-2616. https://doi.org/10.1007/s00405-013-2878-1

Bibtex

@article{9a3441cb13e246c0947b1814f1167117,
title = "Inventory of economic evaluation of head and neck oncology from the German perspective",
abstract = "New treatment strategies for head and neck neoplasms include induction chemotherapy and biomarker treatment. Moreover, different therapeutic modalities, especially robotic surgery, induction chemotherapy, biotherapy and altered fractionation schedules of chemo-(radio)therapy are newly combined to optimize treatment benefit and minimize treatment-associated morbidity. Often, overall survival does not change significantly between the competing treatment schedules. Therefore, the evaluation of the patient's treatment-related quality of life (QoL) and organ function becomes more and more important. Finally, the sponsor's financial resources are restricted, which makes it necessary to evaluate therapies for pricing and effectiveness. In head and neck cancer in Europe, analyses of the current situation are lacking. Selective literature research for publications on economic cost-effectiveness analyses was performed. An overview of the current situation with a special focus on Europe is provided. Cost-effectiveness values and QoL assessments should be respected in former prospective study construction to gain systematic information on this topic.",
author = "Thiemo Kurzweg and R Knecht",
year = "2014",
month = jan,
day = "9",
doi = "10.1007/s00405-013-2878-1",
language = "English",
volume = "271",
pages = "2611--2616",
journal = "EUR ARCH OTO-RHINO-L",
issn = "0937-4477",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Inventory of economic evaluation of head and neck oncology from the German perspective

AU - Kurzweg, Thiemo

AU - Knecht, R

PY - 2014/1/9

Y1 - 2014/1/9

N2 - New treatment strategies for head and neck neoplasms include induction chemotherapy and biomarker treatment. Moreover, different therapeutic modalities, especially robotic surgery, induction chemotherapy, biotherapy and altered fractionation schedules of chemo-(radio)therapy are newly combined to optimize treatment benefit and minimize treatment-associated morbidity. Often, overall survival does not change significantly between the competing treatment schedules. Therefore, the evaluation of the patient's treatment-related quality of life (QoL) and organ function becomes more and more important. Finally, the sponsor's financial resources are restricted, which makes it necessary to evaluate therapies for pricing and effectiveness. In head and neck cancer in Europe, analyses of the current situation are lacking. Selective literature research for publications on economic cost-effectiveness analyses was performed. An overview of the current situation with a special focus on Europe is provided. Cost-effectiveness values and QoL assessments should be respected in former prospective study construction to gain systematic information on this topic.

AB - New treatment strategies for head and neck neoplasms include induction chemotherapy and biomarker treatment. Moreover, different therapeutic modalities, especially robotic surgery, induction chemotherapy, biotherapy and altered fractionation schedules of chemo-(radio)therapy are newly combined to optimize treatment benefit and minimize treatment-associated morbidity. Often, overall survival does not change significantly between the competing treatment schedules. Therefore, the evaluation of the patient's treatment-related quality of life (QoL) and organ function becomes more and more important. Finally, the sponsor's financial resources are restricted, which makes it necessary to evaluate therapies for pricing and effectiveness. In head and neck cancer in Europe, analyses of the current situation are lacking. Selective literature research for publications on economic cost-effectiveness analyses was performed. An overview of the current situation with a special focus on Europe is provided. Cost-effectiveness values and QoL assessments should be respected in former prospective study construction to gain systematic information on this topic.

U2 - 10.1007/s00405-013-2878-1

DO - 10.1007/s00405-013-2878-1

M3 - SCORING: Journal article

C2 - 24402378

VL - 271

SP - 2611

EP - 2616

JO - EUR ARCH OTO-RHINO-L

JF - EUR ARCH OTO-RHINO-L

SN - 0937-4477

IS - 10

ER -